KEYMED BIOSCIENCES -0001 - Asset Resilience Ratio

Latest as of December 2025: 33.68%

KEYMED BIOSCIENCES -0001 (64Z) has an Asset Resilience Ratio of 33.68% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€1.42 Billion

≈ $1.66 Billion USD Cash + Short-term Investments

Total Assets

€4.22 Billion

≈ $4.93 Billion USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how KEYMED BIOSCIENCES -0001's Asset Resilience Ratio has changed over time. See KEYMED BIOSCIENCES -0001 (64Z) flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down KEYMED BIOSCIENCES -0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see KEYMED BIOSCIENCES -0001 stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€1.42 Billion	33.68%
Total Liquid Assets	€1.42 Billion	33.68%

Asset Resilience Insights

Very High Liquidity: KEYMED BIOSCIENCES -0001 maintains exceptional liquid asset reserves at 33.68% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

KEYMED BIOSCIENCES -0001 Industry Peers by Asset Resilience Ratio

Compare KEYMED BIOSCIENCES -0001's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for KEYMED BIOSCIENCES -0001 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for KEYMED BIOSCIENCES -0001.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	33.68%	€1.42 Billion ≈ $1.66 Billion	€4.22 Billion ≈ $4.93 Billion	-12.44pp
2024-12-31	46.12%	€1.74 Billion ≈ $2.03 Billion	€3.77 Billion ≈ $4.40 Billion	-1.99pp
2023-12-31	48.11%	€1.87 Billion ≈ $2.18 Billion	€3.88 Billion ≈ $4.54 Billion	-17.28pp
2022-12-31	65.39%	€2.57 Billion ≈ $3.01 Billion	€3.93 Billion ≈ $4.60 Billion	+14.45pp
2021-12-31	50.93%	€2.00 Billion ≈ $2.34 Billion	€3.93 Billion ≈ $4.60 Billion	--

pp = percentage points

About KEYMED BIOSCIENCES -0001

F:64Z Germany Biotechnology

Market Cap

$2.77 Billion

€2.37 Billion EUR

Market Cap Rank

#5672 Global

#889 in Germany

Share Price

€8.05

Change (1 day)

+0.63%

52-Week Range

€4.94 - €9.55

All Time High

€9.55